tbuckley/cabot-search huggingface dataset:
Abstract 2419: Irradiation of α-ionizing radiation to <i>in vivo</i> glioma model induced metastasis via occurrence of epithelial-mesenchymal transition
Authors: Jong Kuk Park, Su Jin Jang, Sung Wook Kang, Jae-Sung Kim, Sunhoo Park, Sang-Gu Hwang, Joo Hyun Kang, Hong Duck Um
Journal: Cancer Research (2012)

Abstract α-Ionizing radiation (IR) therapy is known to be a one of major therapeutic tools of cancer treatment but α-IR also could be an inducer of tumorigenesis and metastasis. Metastasis is major obstacle and required to overcome for cancer treatment. Therefore, the aim of this investigation was to study whether radiation could induce metastasis our in vivo mouse system, and molecular mechanism behind α-IR-induced metastasis. C6L transfectant cell line expressing firefly luciferase (fLuc) was treated with α-IR and then immunoblotting, zymography and invasion assay in vitro. We also used C6L transfectant cell line to construct xenograft in nude mice and then IR was irradiated to xenograft with α-IR. The irradiated xenograft-containing mice were analyzed with survival curve, measurement of tumor size, and bioluminescence imaging in vivo and ex vivo. We also analyzed metastatic foci in organ of mice with RT-PCR analysis, H &amp; E staining and immunohistochemistry. α-IR treatment to C6L cell induced ocurrence of epithelial-mesenchymal transition (EMT) and increase of cell invasion. In irradiated xenograft-containing mice, sizes of tumor were decreased dramatically and survival rate also extended. Almost all non-irradiated xenograft-containing control mice were dead within 4 weeks. But we also observed luminescence signals in about 20.9% of α-IR treated mice. Intestine or lung of luminescence signal-detected mice contained several foci, which expressed fLuc gene and presented histological features as a cancer tissue as well as expressions of EMT markers. Taken together, these findings indicate that α-IR treatment could induce metastasis in vivo via EMT including increase of MMP activity. We also propose that construction of metastasis animal model by α-IR treatment could use drug development to block cancer metastasis and increase understandings of metastasis mechanism. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2419. doi:1538-7445.AM2012-2419
False-Positive Iodine-131 Whole-Body Imaging Due to Gestational Sac
Authors: YOSHIHIRO NISHIYAMA, YUKA YAMAMOTO, KAZUE TAKAHASHI, SATORU NAKANO, KATASHI SATOH, HITOSHI TAKASHIMA, MOTOOMI OHKAWA, MASATADA TANABE
Journal: Clinical Nuclear Medicine (1998)

A 30-year-old woman underwent total thyroidectomy with bilateral neck dissection for a papillary carcinoma with lymph node metastases. Whole-body imaging with I-131 revealed radioiodine uptake in the pelvis. Ultrasound showed a well-formed 6-week-old gestational sac in the uterus. The gestational sac was found to be the cause of the false-positive I-131 scan.
Unlikely scenarios of 1997
Authors: L. Farrell
Journal: BMJ (1997)

We are approaching that utterly depressing time of year again when the Ulster calendar deviates from the Julian; over here, it's January, February, March, March, March. March: the only verb in the English language which always begins with a capital. Is strife inevitable? Perhaps not if we imagine this unlikely scene.

Orangeman (inhaling deeply): “My child, my flower, my flower child, we were kind of wondering if you'd mind us boogieing along your road.”

Resident : “OK, Rasta-man, come on down and we'll groove on it for a while. And hey, bring some records.”

Orangeman : “Yo, …
Ethical Experimentation and the Editor
Authors: F. Peter Woodford
Journal: New England Journal of Medicine (1972)

Should a journal editor accept for publication manuscripts describing important conclusions from experiments on human subjects that seem to him to have been conducted unethically? The experiments cannot be undone, and the results may be valuable. On the other hand, publication in a reputable journal automatically implies that the editor and his reviewers condone the experimentation. The editor may decide to wash his hands of the problem, publish the work if it is scientifically valid, and let the scientific community judge the ethical aspects. In opposition to this view, the Committee on Editorial Policy of the Council of Biology Editors . . .
GHOSTS AFTER LEAD REMOVAL: ETIOLOGY AND PROGNOSTIC IMPACT. A REPORT OF AN INTRACARDICAC AND TRANSESOPHAGEAL ECHOCARDIOGRAPHIC STUDY
Authors: Carlo Caiati, Giovanni Luzzi, Mario Erminio Lepera, Daniela Santoro, Paolo Pollice, Isabella Lacitignola, Zefferino Palamà, Tommaso Acquaviva, Mario Catalano, Stefano Favale
Journal: Journal of the American College of Cardiology (2016)
FRI0184 Postoperative complications in rheumatoid arthritis patients receiving biologic and nonbiologic disease-modifying antirheumatic drugs:
Authors: E. Pogozheva, V. Amirdzhanova, S. Makarov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To identify complications after total joint arthroplasty in rheumatoid arthritis (RA) patients (pts) treated with biologic and nonbiologic disease-modifying antirheumatic drugs (DMARDs). <h3>Methods</h3> In a retrospective 1:1 pair-matched case–control study 60 pts with RA after total hip arthroplasty (THA) and total knee arthroplasty (TKA), matched in type of surgery and gender, were evaluated for surgical site infection (SSI) and deep venous thrombosis (DVT) in the postoperative period. Pts with RA were split into a biologic group (n=30) treated with biological agents (16 pts - rituximab, 8- infliximab, 3- abatacept and 3- tocilizumab), and a nonbiologic group (n=30) treated only with conventional disease-modifying antirheumatic drugs (21 pts – methotrexate and 4- leflunomide). Nonbiologic DMARDs were continued perioperatively, biologic treatment was stopped and restarted in accordance with Russian guidelines. Baseline characteristics were compared using the Mann-Whitney U-test or Fisher's exact test. <h3>Results</h3> Table 1 shows the baseline characteristics of the pts. For the period from 2 till 12 months after surgery 2 pts (3,3%) had DVT, one pt (1,65%) in biologic group and one (1,65%) in nonbiologic group. Only in nonbiologic group we identified 2 cases (3,3%) with postoperative complications of superficial infections requiring the use of antibiotics. Deep infection was found in only 1 case (1,65%) in biologic group, which was treated with infliximab and necessitated surgical treatment by removal of the artificial joint prosthesis. <h3>Conclusions</h3> In RA patients receiving biologic DMARDs, infections after total joint arthroplasty was rare but potentially more severe. Thus prospective studies are needed to determine the safety of biologic treatment in the perioperative period. <h3>Disclosure of Interest</h3> None Declared
PROGNOSTIC IMPACT OF FAT VOLUME IN PATIENTS ADMITTED FOR ACUTE DECOMPENSATED HEART FAILURE WITH REDUCED OR PRESERVED LEFT VENTRICULAR EJECTION FRACTION
Authors: Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Takumi Kondo, Tatsuhisa Ozaki, Yoshihiro Sato, Masahiro Seo, Iyo Ikeda, Eiji Fukuhara, Masatake Fukunami
Journal: Journal of the American College of Cardiology (2016)
Ceramide Trihexosidosis (Fabry's Disease) without Skin Lesions
Authors: Joe T. R. Clarke, Juergen Knaack, John C. Crawhall, Leonhard S. Wolfe
Journal: New England Journal of Medicine (1971)

Histologic, histochemical and electron microscopical studies of kidney tissue taken by open biopsy from two unrelated men with unexplained proteinuria revealed changes typical of Fabry's disease although neither patient had any other manifestations of the disease. Angiokeratoma and corneal opacities were absent. The diagnoses were confirmed by the demonstration of excessive excretion of trihexosylceramide and digalactosylceramide in the urine. Decreased activities of the leukocyte lysosomal hydrolase, α-galactosidase, were also found in both patients.
PTU-096 Metabolic Bone Disease in Mild Chronic Liver Disease- is it Worth Checking?
Authors: B Patel, S McLaughlin, E Williams, S Al-Shamma
Journal: Gut (2013)

<h3>Introduction</h3> Liver cirrhosis (LC) is increasing in frequency and can cause significant morbidity including metabolic bone disease (MBD) namely osteopaenia and osteoporosis, risk factors of fractures. It is vital that patients with MBD are identified and commenced on appropriate treatment. Whilst studies have investigated the prevalence of MBD in cirrhotics awaiting transplantation, the exact frequency of MBD in mild LC is not known. We aimed to assess the frequency of MBD in patients with mild LC (MELD score &lt; 16) who had undergone DEXA scanning at our instituation to ascertain whether routine screening is worthwhile. <h3>Methods</h3> This was a single-centre retrospective study. From a radiology database, we identified 62 patients with histologically, radiologically and/or clinically diagnosed LC who had undergone a DEXA scan between May 2007 &amp; June 2012. Osteopaenia and osteoporosis were defined using WHO criteria. Contemporaneous bloods were used to calculate the MELD. A similar number of age and sex-matched patients with histologically-confirmed coeliac disease (CD) who had had a DEXA scan were identified to act as a comparison group. The same scanner was used for all patients. <h3>Results</h3> <b><i>Patient characteristics</i></b> We identified 61 patients with LC and 45 with CD. The most common aetiologies were ALD (52%) and PBC (23%). The mean age for cirrhotics was 60.1 years (range 33–78) with 64% M and 36% F. The mean MELD was 10.7 ± 4.1. For those with CD the mean age was 52 years (range 17–82) with 27% M &amp; 73% F. <b><i>Patients with osteoporosis &amp; osteopenia</i></b> Of the cirrhotcis, 57% had MBD (36% osteopenia, 21% osteoporosis) compared to 62% of patients with CD (42% and 20% respectively). 57% of patients with ALD had MBD compared to 71% of patients with PBC. The mean age of those with LC and osteoporosis was 62.4 years (range 47–78) with 54% of patients being male. For those with CD and osteoporosis the mean age was 69 years (range 46–82) with 89% being female. <h3>MBD in male ALD patients</h3> Male ALD patients were at particular risk. There was a statistically significantly higher risk of MBD in male ALD patients (77.8%; 55.8–99.8%) compared to male CD patients (32.1%; 13.1–51.2%; P &lt; 0.05.) On the other hand, female CD patients had a satistically greater risk of MBD vs females with ALD. <h3>MELD score correlation with T-score</h3> We found no correlation between the MELD score and the lumbar or hip T-score (p = 0.803.) Therefore, DEXA screening should be offered to all LC patients regardless of disease severity. <h3>Conclusion</h3> All patients with LC, irrespective of MELD, should undergo DEXA scanning due to the high prevalence of MBD. Male ALD patients warrant particular attention due to the particularly increased risk of MBD and fractures. <h3>Disclosure of Interest</h3> None Declared
Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy
Authors: John E. Cannon, Li Su, David G. Kiely, Kathleen Page, Mark Toshner, Emilia Swietlik, Carmen Treacy, Anie Ponnaberanam, Robin Condliffe, Karen Sheares, Dolores Taboada, John Dunning, Steven Tsui, Choo Ng, Deepa Gopalan, Nicholas Screaton, Charlie Elliot, Simon Gibbs, Luke Howard, Paul Corris, James Lordan, Martin Johnson, Andrew Peacock, Robert MacKenzie-Ross, Benji Schreiber, Gerry Coghlan, Kostas Dimopoulos, Stephen J. Wort, Sean Gaine, Shahin Moledina, David P. Jenkins, Joanna Pepke-Zaba
Journal: Circulation (2016)

Background— Chronic thromboembolic pulmonary hypertension results from incomplete resolution of pulmonary emboli. Pulmonary endarterectomy (PEA) is potentially curative, but residual pulmonary hypertension following surgery is common and its impact on long-term outcome is poorly understood. We wanted to identify factors correlated with poor long-term outcome after surgery and specifically define clinically relevant residual pulmonary hypertension post-PEA. Methods and Results— Eight hundred eighty consecutive patients (mean age, 57 years) underwent PEA for chronic thromboembolic pulmonary hypertension. Patients routinely underwent detailed reassessment with right heart catheterization and noninvasive testing at 3 to 6 months and annually thereafter with discharge if they were clinically stable at 3 to 5 years and did not require pulmonary vasodilator therapy. Cox regressions were used for survival (time-to-event) analyses. Overall survival was 86%, 84%, 79%, and 72% at 1, 3, 5, and 10 years for the whole cohort and 91% and 90% at 1 and 3 years for the recent half of the cohort. The majority of patient deaths after the perioperative period were not attributable to right ventricular failure (chronic thromboembolic pulmonary hypertension). At reassessment, a mean pulmonary artery pressure of ≥30 mm Hg correlated with the initiation of pulmonary vasodilator therapy post-PEA. A mean pulmonary artery pressure of ≥38 mm Hg and pulmonary vascular resistance ≥425 dynes·s −1 ·cm −5 at reassessment correlated with worse long-term survival. Conclusions— Our data confirm excellent long-term survival and maintenance of good functional status post-PEA. Hemodynamic assessment 3 to 6 months and 12 months post-PEA allows stratification of patients at higher risk of dying of chronic thromboembolic pulmonary hypertension and identifies a level of residual pulmonary hypertension that may guide the long-term management of patients postsurgery.
Atrial Arrhythmias after Cardiothoracic Surgery
Authors: Steve R. Ommen, John A. Odell, Marshall S. Stanton
Journal: New England Journal of Medicine (1997)

Atrial tachyarrhythmias early in the recovery period after cardiothoracic surgery are common; they develop in 11 to 40 percent of patients after coronary-artery bypass grafting13 and in over 50 percent of patients after valvular surgery.2 Technical advances in surgery and anesthesia, as well as changing methods of myocardial protection, have not decreased the incidence of postoperative atrial tachyarrhythmias.1,3,4 Although such arrhythmias have been thought of as transient and benign, they may have important consequences. Atrial fibrillation, flutter, and tachycardia are related forms of atrial tachyarrhythmia that may coexist in patients after cardiothoracic surgery and have similar clinical . . .
Depletion of Glutathione in Normal and Malignant Human Cells In Vivo by Buthionine Sulfoximine: Clinical and Biochemical Results
Authors: P. J. O'Dwyer, T. C. Hamilton, R. C. Young, F. P. LaCreta, N. Carp, K. D. Tew, K. Padavic, R. L. Comis, R. F. Ozols
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Depletion of Glutathione in Normal and Malignant Human Cells In Vivo by Buthionine Sulfoximine: Clinical and Biochemical Results Get access P. J. O'Dwyer, P. J. O'Dwyer * Fox Chase Cancer CenterPhiladelphia, Pa. *Correspondence to : P. J. O'Dwyer, M.D., Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme AVE., Philadelphia, PA 19111. Search for other works by this author on: Oxford Academic PubMed Google Scholar T. C. Hamilton, T. C. Hamilton Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar R. C. Young, R. C. Young Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar F. P. LaCreta, F. P. LaCreta Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar N. Carp, N. Carp Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar K. D. Tew, K. D. Tew Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar K. Padavic, K. Padavic Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar R. L. Comis, R. L. Comis Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar R. F. Ozols R. F. Ozols Fox Chase Cancer CenterPhiladelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 4, 19 February 1992, Pages 264–267, https://doi.org/10.1093/jnci/84.4.264 Published: 19 February 1992 Article history Received: 22 April 1991 Revision received: 12 November 1991 Accepted: 04 December 1991 Published: 19 February 1992
735 PEGINTERFERON ADDED TO LONG-TERM NUCLEOS(T)IDE ANALOGUES ENHANCES THE DECLINE OF SERUM HBeAg AND HBsAg LEVELS IN CHRONIC HEPATITIS B
Authors: P. Arends, V. Rijckborst, B.E. Hansen, A.J. van Vuuren, H.L.A. Janssen
Journal: Journal of Hepatology (2013)
Case 16-1998
Authors: Paul E. Sax, Robyn S. Klein, Eugene J. Mark
Journal: New England Journal of Medicine (1998)

Presentation of CaseA 24-year-old man was admitted to the hospital because of the acute respiratory distress syndrome.The patient had been well until several days earlier, when he began to have nasal congestion with green discharge, myalgia, dry cough, mild dyspnea, and a “sinus headache.” A few days before admission, the cough became intermittently productive of rust-colored sputum and was accompanied by right-sided pleuritic pain, fever, chilliness, and diarrhea. On admission to another hospital, the patient's temperature was 38.3°C, and his blood pressure was 145/60 mm Hg. No rash or lymphadenopathy was noted. Consolidation was present over the right . . .
Abstract P5-11-11: Completion of 5-Years Adjuvant Endocrine Therapy in the Community
Authors: B Makubate, C McCowan, JA Dewar, AM. Thompson
Journal: Cancer Research (2010)

Abstract Background: Adjuvant endocrine therapy is recommended by guidelines for all eligible patients with breast cancer for a minimum 5-year period. Shorter periods of treatment and low adherence to medication are associated with worse outcomes for patients. This study examined whether women in the community completed the full course of adjuvant endocrine therapy and whether they were adherent to their medication. Materials and Methods: A cohort of all women diagnosed and treated for breast cancer in the Tayside region of Scotland during the period January 1993 — December 2008 was identified. Information on dispensed prescribing was linked to hospital discharge records, breast cancer clinical audit, cancer registry and death certification for each individual patient. Patients were identified as starting either aromatase inhibitor or tamoxifen therapy with adherence and duration of use subsequently calculated from dispensed prescribing records. Results: 5,729 women were identified with an incident cancer within the study period. 71% were initially prescribed tamoxifen, 8% started aromatase inhibitors and 21% received no adjuvant endocrine therapy. 25% of women who started on aromatase inhibitors switched treatments, with 19% of those on tamoxifen switching. The majority of women had high adherence, the median figure was 91%, but 1,589 (35%) of women had adherence below 80% which was shown in previous work to increase the risk of mortality. For patients followed for at least 1 year, 51 (11%) started on AIs had stopped medication compared to 373 (9%) started on tamoxifen. At year 2, an additional 40 (12%) stopped AIs and 384 (11%) patients stopped tamoxifen. For 3 years follow up, an additional 39 (19%) stopped AIs, while 351 (11%) stopped tamoxifen. For patients followed for at least 4 and 5 years respectively, an additional 22 (26%) then 5 (20%) stopped AIs compared to 297 (11%) and 316 (16%) patients who stopped tamoxifen. Of the 3,613 patients with adequate follow up 1,876 (52%) stopped medication before completing a 5 year period. Conclusions: Half of all patients prescribed adjuvant endocrine therapy stop medication before completing the recommended 5-year period with approximately 20% stopping in the first two years. Over one in three patients have low adherence at a level known to increase the risk of mortality. All patients need to be encouraged to continue their treatment for the recommended 5-year period and to take it daily to ensure they receive maximum benefit from their medication. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-11-11.
CATHETER-DIRECTED THROMBOLYSIS (CDT) VERSUS THROMBOLYSIS TO TREAT PULMONARY EMBOLISM: A PROPENSITY SCORE-MATCHED ANALYSIS FROM THE NATIONWIDE INPATIENT SAMPLE
Authors: Nish Patel, Nileshkumar Patel, Badal Thakkar, Nilay Patel, Shilpkumar Arora, Ankit Chothani, Vikas Singh, Sunny Jhamnani, Sidakpal Panaich, Abhishek Deshmukh, Apurva Badheka, Carlos Alfonso
Journal: Journal of the American College of Cardiology (2015)
Adverse Events After Radiofrequency Ablation in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis
Authors: Bashar J. Qumseya, Sachin Wani, Madhav Desai, Amira Qumseya, Paul Bain, Prateek Sharma, Herbert Wolfsen
Journal: Clinical Gastroenterology and Hepatology (2016)
Unusual case of a stage I thymoma of the posterior mediastinum: endoscopic ultrasound-guided fine needle aspiration alone clinches the diagnosis
Authors: Bronte Holt, Shyam Varadarajulu, Konrad Krall, Shantel Hébert-Magee
Journal: Endoscopy (2014)

Whilst recurrent mediastinal thymoma is not unusual, particularly if the neoplasm was malignant and invasive, there have been few reports confirming tissue acquisition endoscopically, and these have required either core biopsy needles or "special" maneuvers [1] [2]. We present a rare case of recurrent stage I thymoma arising from the posterior mediastinum that was diagnosed on endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) alone, substantiating the role of EUS-FNA in the diagnosis of mediastinal lesions.